TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11124928
Drug: 4% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% w/w amethocaine gel
Study: 3150950
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg per day for 5 days (CC-5)
Study: 3150950
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg per day for 15 days (CC-15)
Study: 15094260
Drug: Paroxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine combined with cognitive group-therapy
Study: 9547164
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid (CSF) levels of soluble IL-6 receptor (sIL-6R) in AD patients
Study: 8341439
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate cream 0.1% applied daily
Study: 8341439
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate cream 0.1% applied twice daily
Study: 29141040
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (oral contraceptive pills Nordette® or Naproxen Naprosyn®)
Study: 25377934
Drug: Control video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control video (oral hygiene instruction)
Study: 23937387
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (25-200 mg bid)
Study: 23937387
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR (5-40 mg bid)
Study: 18435378
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intermediate agent applied)
Study: 16598527
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation in high-risk patients with AF
Study: 10837379
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% three times daily
Study: 9397397
Drug: High-DHA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-DHA diet (6 g/d of DHA in the form of a triglyceride containing 40% DHA)
Study: 9397397
Drug: Low-DHA diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-DHA diet (< 50 mg/d of DHA)
Study: 29684832
Drug: Sucrose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (0.2 ml/kg of 20%) plus non-nutritive sucking group
Study: 29684832
Drug: Sucrose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (0.2 ml/kg of 20%) group
Study: 14730238
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg)
Study: 17452906
Drug: Itraconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (400 mg)
Study: 9308742
Drug: Short prophylaxis
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short prophylaxis with low molecular weight heparin (LMWH) during hospitalisation
Study: 9308742
Drug: Prolonged prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged prophylaxis with low molecular weight heparin (LMWH) for three weeks after hospitalisation
Study: 9308742
Drug: Short prophylaxis
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short prophylaxis with low molecular weight heparin (LMWH)
Study: 7701033
Drug: Naltrexone, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone, 25 mg orally
Study: 3661052
Drug: Aldosterone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone (1.0 mg)
Study: 3661052
Drug: Fluocortolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortolone (20 mg)
Study: 3661052
Drug: Hydrocortisone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (80 mg)
Study: 26413749
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg daily oral spironolactone for 12 weeks
Study: 23444322
Drug: Computer-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based administration of the STOFHLA
Study: 23444322
Drug: Paper-based administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-based administration of the STOFHLA
Study: 22335183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of naltrexone and brief counseling
Study: 22335183
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard tuberculosis treatment without alcohol intervention)
Study: 15911473
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto (study medication)
Study: 10814923
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits
Study: 30178528
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: 7018165
Drug: Natural estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural estrogen (estradiol‐17 beta 4 mg + estriol 2 mg/norethisterone acetate 3 mg per tablet)
Study: 7018165
Drug: Artificial estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial estrogen (ethinyl estradiol 50 micrograms/ norethisterone acetate 3 mg per tablet)
Study: 31438790
Drug: Carpal Tunnel
Normalized name: Wristaleve Carpal Tunnel Brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carpal Tunnel Release surgery with Dexamethasone injection
Study: 23652893
Drug: Nonsteroidal cream
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal cream (Promiseb® Topical Cream); applied topically twice daily for up to 14 days
Study: 23652893
Drug: Placebo cream;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream; applied topically twice daily for up to 14 days
Study: 23652893
Drug: Nonsteroidal cream
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal cream
Study: 21856230
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (150 μg)
Study: 21856230
Drug: Daily recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily recombinant FSH (rFSH) (200 IU)
Study: 19565745
Drug: Bee-needle therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee-needle therapy
Study: 17448376
Drug: BNP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP-guided therapy (goal of decreasing BNP plasma levels <100 pg/ml)
Study: 17448376
Drug: Clinical group
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical group (medical treatment according to current guidelines)
Study: 15334509
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI); 28 days of twice-daily inhalation followed by 28 days off for 56 weeks
Study: 11568032
Drug: Chronic calcium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic calcium channel blocker therapy (CCCBT) continued with diltiazem (120 mg/d) for 5 years
Study: 11568032
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of chronic calcium channel blocker therapy (CCCBT)
Study: 2199619
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (60 weeks)
Study: 686545
Drug: Reinforced disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reinforced disulfiram treatment (methadone contingent upon disulfiram ingestion)
Study: 21197512
Drug: HS +
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS + LA (2% lidocaine in 0.2 ml)
Study: 21197512
Drug: HS +
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS + ketorolac (3 mg in 0.2 mL)
Study: 18295556
Drug: Clopidogrel preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel preparation 1
Study: 18295556
Drug: Clopidogrel preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel preparation 2
Study: 8778554
Drug: Eleutherococcus senticosus
Normalized name: Eleutherococcus Senticosus Root
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eleutherococcus senticosus Maxim L (ESML)
Study: 1667345
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (LAVV)
Study: 6360936
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg daily (group A)
Study: 6360936
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg daily (group B)
Study: 31813866
Drug: 1% aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aspirin gel
Study: 31813866
Drug: 1% aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aspirin mouthwash
Study: 24163120
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg once daily for 6 weeks)
Study: 24163120
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg once daily for 6 weeks)
Study: 20606658
Drug: venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine 75 mg q.h.s. for 4 weeks
Study: 3190970
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg kg‐1
Study: 15276659
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 37.5 mg
Study: 15276659
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 150 mg
Study: 10720128
Drug: Cranial Radiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial Radiation Therapy (CRT)
Study: 10720128
Drug: No Cranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Cranial Radiation Therapy (CRT-)
Study: 8965154
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (2 liters of a nutritive amino acid solution containing approximately 2.25 g/liter lysine‐glutamate and 2.50 g/liter arginine)
Study: 31280997
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (200 mg/kg per hour for the first 8 hours, followed by 100 mg/kg per hour for another 16 hours, same dose for another 24 hours)
Study: 26466684
Drug: First-line antidepressant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antidepressant minimum dosing strategy
Study: 26466684
Drug: First-line antidepressant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antidepressant maximum dosing strategy
Study: 26466684
Drug: Second-line antidepressant
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line antidepressant continuation strategy
Study: 26466684
Drug: Second-line antidepressant
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line antidepressant augmentation strategy
Study: 26466684
Drug: Second-line antidepressant
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line antidepressant switching strategy
Study: 21411151
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL chlorhexidine (CHX) application
Study: 17700131
Drug: Contour I
Normalized name: STOMA CAP,CONTOUR I 50MM H#1796
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contour I device treatment (one treatment in abdomen, thighs, or flanks)
Study: 15499438
Drug: WHO-17D and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO-17D and Brazilian 17DD yellow fever vaccines
Study: 8237624
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg twice daily
Study: 3586503
Drug: Intravenous deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous deferoxamine (2 g)
Study: 3586503
Drug: Intravenous deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous deferoxamine (1 g)
Study: 3586503
Drug: Intramuscular deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular deferoxamine (1 g)
Study: 3586503
Drug: Intraperitoneal deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal deferoxamine (2 g)
Study: 3586503
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intraperitoneal deferoxamine
Study: 28034064
Drug: Three-Dimensional Conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-Dimensional Conformal External Beam Radiation Therapy (3D-CRT)
Study: 26579041
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBTp)
Study: 19549094
Drug: Rosuvastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10-40 mg OD)
Study: 19549094
Drug: Atorvastatin (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20-80 mg OD)
Study: 19549094
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg OD)
Study: 19549094
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg OD)
Study: 10735790
Drug: Remifentanil (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.25 microg. kg(‐1). min(‐1) continuous infusion)
Study: 10735790
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg bolus followed by placebo continuous infusion)
Study: 8737620
Drug: Intranasal carbocalcitonin
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal carbocalcitonin (80 U MRC daily for 12 months)
Study: 1591369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cisplatin, decarbazine, carmustine, and tamoxifen
Study: 1591369
Drug: Biological response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biological response modifiers (interleukin‐2 and alpha‐interferon)
Study: 29424335
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (entecavir tablet)
Study: 29424335
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (entecavir tablet)
Study: 19901102
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg twice daily
Study: 20118030
Drug: Prophylactic pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prophylactic pegfilgrastim use (all cycles of chemotherapy)
Study: 7021266
Drug: Fentiazac 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentiazac 5% cream
Study: 31260794
Drug: Weight-driven recommendation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-driven recommendation of restricted fluid intake, diuretics, and ultrafiltration initiated from 48 hours up to 14 days after admission.
Study: 26187183
Drug: Simplified cardiovascular
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified cardiovascular management program delivered by community health workers using an Android app, focusing on medication use and lifestyle modifications.
Study: 24172699
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus alpha-lipoic acid 300 mg twice daily
Study: 21645507
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 μg twice a day (titrated to 10 μg twice a day after 1 month)
Study: 21645507
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg three times a day (titrated to 2 mg three times a day after 1 month)
Study: 19468259
Drug: Standard procedure
Normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure to reach a treatment agreement (control)
Study: 15232804
Drug: Sevoflurane 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 2% added to cardioplegia solution
Study: 11389784
Drug: Estrogen or
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen or hormone replacement therapy (ERT or HRT)
Study: 9517609
Drug: Beclomethasone dipropionate,
Normalized name: Beclomethasone Dipropionate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate, 84 microg twice a day
Study: 3191663
Drug: Timolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (non-selective beta-blocker, 10 mg b.i.d. for 5 days)
Study: 3191663
Drug: Metoprolol (beta-1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta-1-selective beta-blocker, 100 mg b.i.d. for 5 days)
Study: 3191663
Drug: Timolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (non-selective beta-blocker)
Study: 3191663
Drug: Metoprolol (beta-1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta-1-selective beta-blocker)
Study: 26682793
Drug: Both beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both beta-blockers
Study: 30283184
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (30 mg/kg loading dose over 15 min, followed by 10 mg/kg/h for 1 h)
Study: 30283184
Drug: Paracetamol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (10 mg/kg infusion started with induction and continued for 1 h)
Study: 25407227
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention consisting of olive oil for cooking, an olive oil based spread, and a daily supplement drink enriched with Vitamin D (10 microgram daily) and marine omega‐3 fatty acids (2 g daily) for 6 weeks preconception
Study: 25407227
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet of sunflower seed oil for cooking, a sunflower oil based spread, and a daily supplement drink without added Vitamin D or marine omega‐3 fatty acids
Study: 22957013
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment at a dose of 50 IU/kg/week for 3 injections over 18 days
Study: 8678066
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EPO treatment)
Study: 19440168
Drug: Discoblock (intradisc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discoblock (intradisc injection of 0.75 mL of 0.5% bupivacaine)
Study: 19440168
Drug: Discography (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discography (1.5 mL of contrast medium)
Study: 12701864
Drug: BSE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSE with postoperative MMC 0.02% drops twice a day for 5 days
Study: 8818848
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg three times daily for 10 days
Study: 1373360
Drug: Tamoxifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (30 mg/day)
Study: 26002873
Drug: Integrated Violence
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Violence Prevention Treatment (IVPT)
Study: 22868247
Drug: Intermittent LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent LHRH therapy
Study: 22868247
Drug: Continuous LHRH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous LHRH therapy
Study: 19684500
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment for 12 sessions (5 sessions per week)
Study: 17373863
Drug: First ONS
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: First ONS (oral nutritional supplement)
Study: 9404990
Drug: Op-Site treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Op-Site treatment
Study: 7506159
Drug: Nimesulide 200mg
Normalized name: nimesulide 200 MG
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200mg twice daily
Study: 7506159
Drug: Naproxen 500mg
Normalized name: NAPROXEN 500MG TAB
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg twice daily
Study: 3711534
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral dipyridamole
Study: 3711534
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral dipyridamole
Study: 3711534
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole (200 or 400 mg)
Study: 31729600
Drug: R,S‐1,3‐butanediol (BD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R,S‐1,3‐butanediol (BD) 0.35 g kg‐1